Amid the increase in COVID-19 coronavirus cases in India, the central government expects that between 400 and 500 million doses of the vaccine will be available in the country in 2021. Union Health Minister Dr. Harsh Vardhan, chaired a meeting of a group of ministers on Tuesday in Delhi. to hold discussions on the scenario of vaccines against the coronavirus, both Indian and international.
“Keeping pace close to the potential availability of the vaccine, an action plan on which sections will be prioritized has been discussed. Importantly, it would be monitored using a scientific approach,” Harsh Vardhan told ANI.
“To this end, the strategies that the world have adopted, be it the United States Center for Disease Control, are being continuously studied. Digital platforms are also being prepared for the same,” he added.
It should be noted that the Center commissioned the National Group of Experts on Vaccine Administration, headed by Dr. VK Paul, to develop strategies to plan how to implement the distribution of the vaccine in the country. The high-level panel includes AIIMS Director Dr. Randeep Guleria, representatives from Ministries of Foreign Affairs, Biotechnology, Information Technology, Director General of Health Services, AIDS Research Institute of India , the Medical Research Council of India and also representatives of the states.
Dr. VK Paul presented a “comprehensive study on priority population sectors that would have initial access to the vaccine based on the recommendations of the CDC, US and WHO,” during Tuesday’s meeting, according to a statement. issued by the ministry of health. and family welfare.
“The eVIN network that can track the latest vaccine stock position, temperature in storage facilities, geotag health centers, and maintain facility-level dashboard is being reused for COVID vaccine delivery,” added the ministry.
According to Paul, the vaccine will be distributed first to those who need it most and the roster of healthcare workers will be completed in late October or early November.
On live Tv
A total of three candidate vaccines are currently in different stages of clinical trials in India. Covaxin, which is being developed by Bharat Biotech International Limited in conjunction with the Indian Council for Medical Research and the National Institute of Virology, was the first indigenous vaccine candidate to combat COVID-19. Covaxin is currently in phase II human trials in the country.
.
